Search

Displaying results 5581 - 5590 of 10000 in total
  1. Drug

    NE-180

    go.drugbank.com/drugs/DB05619
    Experimental

    NE-180 was under investigation in a clinical trial conducted in the European Union.

  2. Drug

    Hydroxyethyl ethylcellulose

    go.drugbank.com/drugs/DB14139
    Approved

    Hydroxyethyl ethylcellulose modulates bacterial binding to salivary pellicle; moderately effective in preventing plaque formation.

  3. Drug

    Betulinic Acid

    go.drugbank.com/drugs/DB12480
    ApprovedWithdrawn

    Betulinic Acid has been used in trials studying the treatment of Dysplastic Nevus Syndrome.

  4. Drug

    Digoxin Immune Fab (Ovine)

    go.drugbank.com/drugs/DB00076
    Approved

    Digoxin Immune Fab is a sheep antibody (26-10) FAB fragment from sheep immunized with the digoxin derivative Digoxindicarboxymethylamine. It is used as an antidote for overdose of digoxin.

  5. Drug

    Laropiprant

    go.drugbank.com/drugs/DB11629
    ApprovedWithdrawn

    Laropiprant is an ingredient in the EMA-withdrawn product Pelzont.

  6. Drug

    Biguanide

    go.drugbank.com/drugs/DB13100
    ApprovedInvestigationalWithdrawn

    Biguanide has been investigated for the treatment of Diabetes Mellitus.

  7. Drug

    Ganulameran

    go.drugbank.com/drugs/DB16442
    Investigational

    The BNT162b3 vaccine is the latest addition to BioNTech and partner Pfizer’s mRNA COVID-19 vaccine program. Similar to [BNT162b2], BNT162b3 uses a nucleoside-modified RNA (modRNA) technology. … Pfizer and BioNTech deemed this compound as promising in preclinical trials and have decided to initiate further testing of it.

  8. Drug

    Piclamilast

    go.drugbank.com/drugs/DB01791
    Experimental

    It has been investigated for its applications to the treatment of conditions such as chronic obstructive pulmonary disease, bronchopulmonary dysplasia and asthma. … The structure for piclamilast was first elucidated in a 1995 European patent application and exhibits the structural functionalities of cilomilast and roflumilast.

  9. Drug

    Olinciguat

    go.drugbank.com/drugs/DB15238
    Investigational

    Olinciguat is under investigation in clinical trial NCT03892499 (A Trial to Evaluate the Effect of Itraconazole (ITZ), a CYP3A4 Inhibitor, on the Pharmacokinetics of the Soluble Guanylate Cyclase Stimulator

  10. Drug

    VY-HTT01

    go.drugbank.com/drugs/DB16999
    Investigational

    VY-HTT01 is a gene therapy designed to reduce the expression of huntingtin, thereby altering disease progression. … VY-HTT01 is comprised of an adeno-associated virus capsid (AAV1) and a proprietary transgene that harnesses the canonical RNA interference pathway to selectively knock down levels of HTT mRNA.